CARLSBAD, Calif., Sept. Feb. 22, 2022 (GLOBE NEWSWIRE) — Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, announced today that João Siffert, MD, President and CEO, and Sean Jeffries, Ph.D., Chief Operating Officer, will participate in a fireside chat during the Jefferies Cell and Genetic Medicine Summit 2022 on Thursday, September 29, 2022 at 10:00 a.m. ET in New York.
A live webcast will be available in the Investors section of the Company’s website at www.designtx.com and will be archived for 30 days following the presentation.
About Design Therapeutics
Design Therapeutics is a clinical-stage biotechnology company developing a new class of therapies based on its GeneTAC™ gene-targeted chimeric small molecule platform. The company’s GeneTAC™ molecules are designed to increase or decrease the expression of a specific pathogenic gene to treat the underlying cause of the disease. Design’s primary program is focused on the treatment of Friedreich’s Ataxia, followed by a program in myotonic dystrophy type 1 and discovery efforts for several other serious degenerative disorders caused by repeated nucleotide expansions. For more information, visit designtx.com.
#Design #Therapeutics #Present #Jefferies #Cell #Genetic #Medicine #Summit